Inhibition of angiogenesis by antibody blocking the action of proangiogenic high‐molecular‐weight kininogen

Summary.  Previously we demonstrated that domain 5 (D5) of high‐molecular‐weight kininogen (HK) inhibits neovascularization in the chicken chorioallantoic membrane (CAM) assay and further found that kallikrein cleaved HK (HKa) inhibited FGF2‐and VEGF‐induced neovascularization, and thus was antiangiogenic. In this study, we sought to demonstrate whether uncleaved HK stimulates neovascularization and thus is proangiogenic. The chick chorioallantoic membrane was used as an in ovo assay of angiogenesis. Low‐molecular‐weight kininogen stimulates angiogenesis, indicating that D5 is not involved. Bradykinin stimulates neovascularization equally to HK and LK and is likely to be responsible for the effect of HK. A murine monoclonal antibody to HK (C11C1) also recognizes a similar component in chicken plasma as detected by surface plasmon resonance. Angiogenesis induced by FGF2 and VEGF is inhibited by this monoclonal antibody and is a more potent inhibitor of neovascularization induced by VEGF than an integrin αvβ3 antibody (LM 609). Our postulate that C11C1 inhibits the stimulation of angiogenesis by HK was confirmed when either C11C1 or D5 completely inhibited angiogenesis in the CAM induced by HK. Growth of human fibrosarcoma (HT‐1080) on the CAM was inhibited by GST‐D5 and C11C1. These results indicate HK is proangiogenic probably by releasing bradykinin and that a monoclonal antibody directed to HK could serve as an antiangiogenic agent with a potential for inhibiting tumor angiogenesis and other angiogenesis‐mediated disorders.

[1]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[2]  R. Colman,et al.  The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc‐dependent binding to an anionic surface , 1992, Protein science : a publication of the Protein Society.

[3]  R. Colman,et al.  Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. , 1984, The Journal of clinical investigation.

[4]  K. Austen,et al.  Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Miyata,et al.  Structural organization of the human kininogen gene and a model for its evolution. , 1985, The Journal of biological chemistry.

[6]  R. Colman,et al.  Kininostatin, an Angiogenic Inhibitor, Inhibits Proliferation and Induces Apoptosis of Human Endothelial Cells , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. Lämmle,et al.  High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326 , 2000, Thrombosis and Haemostasis.

[8]  R. Colman,et al.  Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. , 2000, Blood.

[9]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[10]  V. Donaldson,et al.  Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen. , 1987, The Journal of laboratory and clinical medicine.

[11]  A. Schmaier,et al.  Conformational Changes in Low Molecular Weight Kininogen Alters Its Ability to Bind to Endothelial Cells , 1995, Thrombosis and Haemostasis.

[12]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.

[13]  A. Vaheri,et al.  Directed plasminogen activation at the surface of normal and malignant cells. , 1991, Advances in cancer research.

[14]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[15]  R. Colman,et al.  Deletion mutagenesis of high molecular weight kininogen light chain. Identification of two anionic surface binding subdomains. , 1993, The Journal of biological chemistry.

[16]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[17]  R. Colman,et al.  Epitope mapping of functional domains of human factor Va with human and murine monoclonal antibodies. Evidence for the interaction of heavy chain with factor Xa and calcium. , 1987, Blood.

[18]  A. Schmaier,et al.  Determination of the bifunctional properties of high molecular weight kininogen by studies with monoclonal antibodies directed to each of its chains. , 1987, The Journal of biological chemistry.

[19]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[20]  R. Colman,et al.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. , 1997, The Journal of clinical investigation.

[21]  D. Mosher,et al.  Inhibition of cell adhesion by high molecular weight kininogen , 1992, The Journal of cell biology.

[22]  A. Schmaier,et al.  Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5 (*) , 1995, The Journal of Biological Chemistry.

[23]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[24]  R. Colman,et al.  Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. , 2000, Blood.

[25]  D. Shaw,et al.  Two‐chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  A. Schmaier,et al.  The pharmacokinetics of the kininogens. , 1998, Thrombosis Research.

[27]  R. Colman,et al.  Three noncontiguous peptides comprise binding sites on high-molecular-weight kininogen to neutrophils. , 1998, American journal of physiology. Heart and circulatory physiology.

[28]  A. Schmaier,et al.  High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets , 1989, The Journal of cell biology.

[29]  F. Bayard,et al.  Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. , 1996, Diabetes & metabolism.

[30]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[31]  R. Colman,et al.  High-molecular-weight kininogen preadsorbed to glass surface markedly reduces neutrophil adhesion. , 2000, Biomaterials.

[32]  Yan-Lin Guo,et al.  Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. , 2004, Blood.

[33]  H. Granger,et al.  The bradykinin/B1 receptor promotes angiogenesis by up‐regulation of endogenous FGF‐2 in endothelium via the nitric oxide synthase pathway , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  T. Sueyoshi,et al.  Isolation and characterization of ornitho-kininogen. , 1987, European journal of biochemistry.

[35]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[36]  J. Folkman,et al.  The Hemostatic System as a Regulator of Angiogenesis* , 2000, The Journal of Biological Chemistry.